文献速递妇科

尼拉帕利与安慰剂治疗复发性卵巢癌患者的长期安全性:III期ENGOT-OV16/NOVA试验结果

Long-term safety in patients with recurrent ovarian cancer treated with niraparib versus placebo: Results from the phase III ENGOT-OV16/NOVA trial.
PubMed 文献 · Gynecol Oncol · 2020-09-25

该多中心、双盲、随机对照III期试验评估尼拉帕利治疗复发性卵巢癌的长期安全性。367例患者接受尼拉帕利300 mg每日一次,因不良事件减量第1个月最高(34%),≥3级血小板减少从第1个月28%降至第2、3个月9%和5%。结论支持按毒性标准适当减量及尼拉帕利长期维持治疗的安全性。

要点

  • 尼拉帕利组因治疗中出现的不良事件减量在第1个月最高(34%),此后逐月下降。
  • ≥3级血小板减少从第1个月28%降至第2个月9%、第3个月5%,伴方案指导的暂停和/或减量。
  • 尼拉帕利组报告急性髓系白血病2例、骨髓增生异常综合征6例,安慰剂组各1例。

核心结论

  • 数据表明按毒性标准适当减量很重要,并支持尼拉帕利用于复发性卵巢癌维持治疗的长期安全性。

研究设计与样本

  • 多中心、双盲、随机对照III期试验,按胚系BRCA突变状态入组两个独立队列,按2:1随机接受尼拉帕利300 mg每日一次或安慰剂。
  • 长期安全性数据来自最近一次数据截止(2017年9月)。
  • 共367例患者接受尼拉帕利300 mg每日一次。

主要发现

  • 因治疗中出现的不良事件减量在第1个月最高(34%),此后逐月下降。
  • 任何级别和≥3级血液学及症状性治疗中出现的不良事件发生率均在第1个月最高,随后下降。
  • ≥3级血小板减少从第1个月28%降至第2个月9%和第3个月5%,伴方案指导的暂停和/或减量。
  • 尼拉帕利组报告急性髓系白血病2例、骨髓增生异常综合征6例,安慰剂组各1例。
  • 每个月份和时间区间因治疗中出现的不良事件停药率均<5%。

关键数值与推荐

  • 尼拉帕利剂量为300 mg每日一次。
  • 随机分组比例为2:1(尼拉帕利:安慰剂)。

临床怎么用

  • 作者认为按毒性标准适当减量很重要,并支持尼拉帕利用于复发性卵巢癌维持治疗的长期安全性。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Niraparib is a poly(ADP-ribose) polymerase (PARP) inhibitor approved for use in heavily pretreated patients and as maintenance treatment in patients with newly-diagnosed or recurrent ovarian cancer following a response to platinum-based chemotherapy. We present long-term safety data for niraparib from the ENGOT-OV16/NOVA trial. METHODS: This multicenter, double-blind, randomized, controlled phase III trial evaluated the efficacy and safety of niraparib for the treatment of recurrent ovarian cancer. Patients were randomly assigned 2:1 to receive either once-daily niraparib 300 mg or placebo. Two independent cohorts were enrolled based on germline BRCA mutation status. The primary endpoint was progression-free survival, reported previously. Long-term safety data were from the most recent data cutoff (September 2017). RESULTS: Overall, 367 patients received niraparib 300 mg once daily. Dose reductions due to TEAEs were highest in month 1 (34%) and declined every month thereafter. Incidence of any-grade and grade ≥ 3 hematologic and symptomatic TEAEs was also highest in month 1 and subsequently declined. Incidence of grade ≥ 3 thrombocytopenia decreased from 28% (month 1) to 9% and 5% (months 2 and 3, respectively), with protocol-directed dose interruptions and/or reductions. Acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) were reported in 2 and 6 niraparib-treated patients, respectively, and in 1 placebo patient each. Treatment discontinuations due to TEAEs were <5% in each month and time interval measured. CONCLUSION: These data demonstrate the importance of appropriate dose reduction according to toxicity criteria and support the safe long-term use of niraparib for maintenance treatment in patients with recurrent ovarian cancer. TRIAL REGISTRATION: ClinicalTrials.gov identifier: NCT01847274.

来源:Gynecol Oncol,查看原文。版权归原作者所有。

引用

  1. Mirza MR, Benigno B, Dørum A, et al. Long-term safety in patients with recurrent ovarian cancer treated with niraparib versus placebo: Results from the phase III ENGOT-OV16/NOVA trial. Gynecol Oncol. 2020. PMID: 32981695. doi:10.1016/j.ygyno.2020.09.006

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。